e-learning
resources
ERJ
2012
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Prognostic power of proadrenomedullin in community-acquired pneumonia is independent of aetiology
Bello Salvador, Lasierra Ana B., Mincholé Elisa, Fandos Sergio, Ruiz Maria Angeles, Vera Elisabeth, de Pablo Francisco, Ferrer Miguel, Menendez Rosario, Torres Antoni
Source:
Eur Respir J 2012; 39: 1144-1155
Journal Issue:
May
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Bello Salvador, Lasierra Ana B., Mincholé Elisa, Fandos Sergio, Ruiz Maria Angeles, Vera Elisabeth, de Pablo Francisco, Ferrer Miguel, Menendez Rosario, Torres Antoni. Prognostic power of proadrenomedullin in community-acquired pneumonia is independent of aetiology. Eur Respir J 2012; 39: 1144-1155
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Middle-long term pulmonary abnormalities after severe COVID-19 pneumonia which required invasive ventilation
Related content which might interest you:
MR-proANP and prognosis of ventilator-associated pneumonia
Source: Annual Congress 2009 - Ventilator-associated pneumonia, severe community-acquired pneumonia and healthcare associated pneumonia
Year: 2009
Pro-atrial natriuretic peptide and pro-vasopressin to predict severity and prognosis in community-acquired pneumonia
Source: Eur Respir J 2007; 30: Suppl. 51, 481s
Year: 2007
Prognostic factors of mortality in patients with community-acquired pneumonia (CAP)
Source: Eur Respir J 2003; 22: Suppl. 45, 239s
Year: 2003
Biomarkers for the prognostic assessment and disease severity evaluation in community-acquired pneumonia (CAP)
Source: Annual Congress 2010 - The prognosis of community-acquired pneumonia: old and new markers of severity
Year: 2010
Pro-adrenomedullin, pro-atrial natriuretic peptide and procalcitonin levels at admission in patients with community-acquired pneumonia and its correlation with risk scores
Source: Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia
Year: 2011
Copeptin and prognosis of ventilator-associated pneumonia
Source: Annual Congress 2008 - Features of hospital-acquired pneumonia, ventilator-associated pneumonia and infection with other pathogens
Year: 2008
Role of procalcitonin in predicting severity and in-hospital mortality in patients with community-acquired pneumonia
Source: International Congress 2016 – Community-acquired pneumonia: risk classes and management issues
Year: 2016
Management-based risk prediction in community-acquired pneumonia by scores and biomarkers
Source: Eur Respir J 2013; 41: 974-984
Year: 2013
Diagnostic and prognostic utility of procalcitonin (PCT) measurements in patients with hospitalized community-acquired pneumonia (CAP)
Source: Annual Congress 2009 - Assessment of severity in respiratory infections: severity scales and biomarkers
Year: 2009
Copeptin application in severe community-acquired pneumonia (SCAP) severity assessment and outcomes
Source: Annual Congress 2012 - Respiratory infections: a clinical point of view
Year: 2012
Value of bacteraemia as an unfavourable prognostic factor for community-acquired pneumonia
Source: Eur Respir J 2006; 28: Suppl. 50, 350s
Year: 2006
Diagnostic and prognostic value of C-reactive protein in community-acquired pneumonia hospitalized patients
Source: Eur Respir J 2004; 24: Suppl. 48, 188s
Year: 2004
The assessment of prognostic rules in patients with community-acquired pneumonia (CAP)
Source: Eur Respir J 2003; 22: Suppl. 45, 149s
Year: 2003
Biomarkers and severity in community-acquired pneumonia (CAP)
Source: Annual Congress 2012 - Prognostic indices in respiratory infections
Year: 2012
Midregional pro-atrial natriuretic peptide and procalcitonin improve survival prediction in VAP
Source: Eur Respir J 2011; 37: 595-603
Year: 2011
Prognostic value of procalcitonin in community-acquired pneumonia
Source: Eur Respir J 2011; 37: 384
Year: 2011
Procalcitonin as etiological marker of severe community-acquired pneumonia
Source: Annual Congress 2013 –Interesting cases of respiratory infections
Year: 2013
Prognostic value of plasma D-dimer level in adults with community-acquired pneumonia – A prospective study
Source: International Congress 2015 – CAP: prognostic factors in frail patients
Year: 2015
Predictive and prognostic factors in patients with blood-culture-positive community-acquired pneumococcal pneumonia
Source: Eur Respir J 2016; 48: 797-807
Year: 2016
Procalcitonin and D-dimer to predict prognosis and clinical outcomes in severe community-acquired pneumonia (SCAP) patients
Source: Annual Congress 2012 - Respiratory infections: a clinical point of view
Year: 2012
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept